
Phreesia Inc (PHR) Stock Forecast & Price Target
Phreesia Inc (PHR) Analyst Ratings
Bulls say
Phreesia is a leading provider of integrated software, payments, and engagement platform for healthcare organizations. The company's platform is designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Despite a sequential decline in subscription revenue due to deliberate pricing actions, management is prioritizing retention, client ROI, and platform monetization which will likely result in sustainable growth and a structural advantage over competitors. The company's strong reputation in the market, along with its ability to monetize customers across multiple revenue streams, positions them well for success in the constantly evolving healthcare industry. In addition, the recent acquisition of AccessOne and a partnership with OpenEvidence are expected to contribute to future growth. While there are some headwinds in the industry, such as the pharma patent cliff and competition for healthcare ad budgets, Phreesia is well-positioned to navigate these challenges and continue its upward trajectory.
Bears say
Phreesia is facing several challenges that could negatively impact its stock. The company relies heavily on its Phreesia Platform to generate revenue, but it faces tough competition from other healthcare software companies. Its revenue growth has slowed down in recent quarters, and it may struggle to maintain its current valuation in a market where investors are increasingly cautious about the healthcare sector. In addition, Phreesia's expected revenue from its CueSquared business has not matched expectations, and its missing revenue from Network Solutions is eating into its margin opportunities.
This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.
Phreesia Inc (PHR) Analyst Forecast & Price Prediction
Start investing in Phreesia Inc (PHR)
Order type
Buy in
Order amount
Est. shares
0 shares